

**THRU ONLINE FILING**

June 16, 2020

BSE Limited  
Phiroze Jeejeebhoy Towers  
27<sup>th</sup> Floor, Dalal Street  
Mumbai 400 023

The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Flr, Plot # C/1  
G Block, Bandra-Kurla Complex,  
Bandra (E), Mumbai 400 051.

Dear Sir,

A. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following which were taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai :

- (i) Audited Financial Results (Standalone) for the 4<sup>th</sup> quarter and financial year ended 31<sup>st</sup> March, 2020;
- (ii) Report of the Auditors on the Audited Financial Results (Standalone) for the 4<sup>th</sup> quarter and financial year ended 31<sup>st</sup> March, 2020;
- (iii) Audited Financial Results (Consolidated) for the financial year ended 31<sup>st</sup> March, 2020; and
- (iv) Report of the Auditors on the Audited Financial Results (Consolidated) for the financial year ended 31<sup>st</sup> March, 2020.

B. We are also enclosing herewith a declaration stating that the Audit Reports on Standalone and Consolidated Financial Results for the financial year ended 31<sup>st</sup> March, 2020 are with unmodified opinion.


C. We are also enclosing herewith a press release issued by the Company in respect of its FY 2019-20 Audited Financial Results.

Kindly note that the Board meeting started at 12.00 noon and concluded at 1.30 p.m.

Thanking you,

Yours faithfully

For Ipca Laboratories Limited



Harish Kamath

Corporate Counsel &amp; Company Secretary

**Ipca Laboratories Ltd.**  
**www.ipca.com**

**Ipca Laboratories Limited**

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

**AUDITED STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020**

(₹ Crores)


Sr. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2020 Audited*	Dec 31, 2019 Unaudited	March 31, 2019 Audited*	March 31, 2020 Audited	March 31, 2019 Audited
I	Revenue from operations	1004.79	1139.07	833.81	4367.43	3633.15
II	Other Income	13.30	17.63	14.58	64.69	54.59
III	<b>Total Income (I+II)</b>	<b>1018.09</b>	<b>1156.70</b>	<b>848.39</b>	<b>4432.12</b>	<b>3687.74</b>
IV	Expenses					
	a) Cost of materials consumed	371.06	350.63	266.14	1431.10	1098.02
	b) Purchases of stock-in-trade	50.85	53.98	44.04	204.65	167.87
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(94.97)	(23.08)	(41.21)	(155.05)	(106.14)
	d) Employee benefits expense	227.88	217.72	176.82	870.79	752.24
	e) Finance costs	3.47	3.80	6.25	15.79	18.49
	f) Depreciation and amortisation expense	45.38	46.16	41.61	178.69	171.88
	g) Other expenses	257.25	274.38	213.35	1101.18	1027.99
	<b>Total Expenses (IV)</b>	<b>860.92</b>	<b>923.59</b>	<b>707.00</b>	<b>3647.15</b>	<b>3130.35</b>
V	<b>Profit before exceptional items and tax (III-IV)</b>	<b>157.17</b>	<b>233.11</b>	<b>141.39</b>	<b>784.97</b>	<b>557.39</b>
VI	Exceptional items	-	-	-	-	-
VII	<b>Profit before tax (V-VI)</b>	<b>157.17</b>	<b>233.11</b>	<b>141.39</b>	<b>784.97</b>	<b>557.39</b>
VIII	Tax Expense					
	-Current tax	28.18	40.78	30.90	137.98	119.90
	-Short / (Excess) provision of earlier years	-	-	-	-	(5.02)
	-Deferred tax liability / (asset) including MAT credit	1.23	(4.30)	1.02	(5.47)	(12.40)
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>127.76</b>	<b>196.63</b>	<b>109.47</b>	<b>652.46</b>	<b>454.91</b>
X	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss -					
	- Actuarial gain/(loss)	(2.64)	(0.61)	(4.66)	(7.21)	(1.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.45	0.11	1.00	1.25	0.30
	B (i) Items that will be reclassified to profit or loss					
	- Exchange difference in translating the financial statement of foreign operation	(0.62)	0.23	(0.26)	(0.60)	(0.64)
	- Gain/(loss) on cash flow hedge	(0.76)	0.12	(0.36)	(1.47)	(3.41)
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.24	(0.04)	-	0.36	-
	<b>Other Comprehensive Income / (Loss) for the period net of tax (X)</b>	<b>(3.33)</b>	<b>(0.19)</b>	<b>(4.28)</b>	<b>(7.67)</b>	<b>(5.14)</b>
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>124.43</b>	<b>196.44</b>	<b>105.19</b>	<b>644.79</b>	<b>449.77</b>
XII	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.27	25.27	25.27	25.27
XIII	Other Equity	-	-	-	3,640.33	3111.39
XIV	Share Warrant	-	-	-	11.94	-
XV	Net Worth	-	-	-	3,677.54	3136.66
XVI	Earnings per share (of ₹ 2/- each) (Not annualised):					
	Basic (₹)	10.11	15.56	8.67	51.64	36.01
	Diluted (₹)	10.10	15.56	8.67	51.60	36.01



## AUDITED STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT MARCH 31, 2020

(₹ Crores)


Sr. No.	Particulars	Unaudited	Audited
		March 31, 2020	March 31, 2019
<b>A</b>	<b>ASSETS :</b>		
<b>1</b>	<b>Non-current assets :</b>		
(a)	Property, Plant and Equipment	1772.78	1706.35
(b)	Capital work-in-progress	69.77	35.72
(c)	Goodwill	23.61	23.61
(d)	Other Intangible assets	18.45	10.14
(e)	Intangible assets under development	14.42	30.24
(f)	Right of use asset	26.13	-
(g)	Financial Assets		
	(i) Investments in Subsidiary/Joint Venture/Associate	410.47	231.86
	(ii) Other investments	-	-
	(iii) Loans	98.98	116.96
	(iv) Others	10.64	3.24
(h)	Other non-current assets	27.21	13.87
	<b>Total Non current assets</b>	<b>2472.46</b>	<b>2171.99</b>
<b>2</b>	<b>Current assets :</b>		
(a)	Inventories	1266.96	1055.55
(b)	Financial Assets		
	(i) Investments	238.25	90.38
	(ii) Trade receivables	839.13	632.06
	(iii) Cash and cash equivalents	35.14	258.69
	(iv) Bank Balance other than (iii) above	117.26	1.12
	(v) Loans	3.22	2.12
	(vi) Others	80.45	104.51
(c)	Current tax assets	-	-
(d)	Other current assets	131.70	141.12
	<b>Total Current assets</b>	<b>2712.11</b>	<b>2285.55</b>
	<b>Total Assets</b>	<b>5184.57</b>	<b>4457.54</b>
<b>B</b>	<b>EQUITY AND LIABILITIES :</b>		
	<b>Equity :</b>		
(a)	Equity Share Capital	25.27	25.27
(b)	Share Warrant	11.94	-
(c)	Other Equity	3640.33	3111.39
	<b>Total Equity</b>	<b>3677.54</b>	<b>3136.66</b>
	<b>Liabilities :</b>		
<b>1</b>	<b>Non-current liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	78.38	133.94
	(ii) Lease liability	13.02	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	30.98	25.28
(c)	Deferred tax liabilities (net)	140.79	146.26
(d)	Other non-current liabilities	2.26	1.56
	<b>Total Non current liabilities</b>	<b>265.43</b>	<b>307.04</b>
<b>2</b>	<b>Current liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	309.27	195.86
	(ii) Lease liability	5.87	-
	(iii) Trade payables		
	- Dues of micro and small enterprises	8.28	4.34
	- Dues of others	529.57	459.75
	(iv) Other financial liabilities	137.74	196.91
(b)	Current Tax Liabilities (net)	6.75	16.55
(c)	Provisions	92.85	70.40
(d)	Other current liabilities	151.27	70.03
	<b>Total Current liabilities</b>	<b>1241.60</b>	<b>1013.84</b>
	<b>Total Equity and Liabilities</b>	<b>5184.57</b>	<b>4457.54</b>



**Notes:**


- 1 The above audited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on June 16, 2020.
- 2 The Company's Resolution Plan under the Insolvency and Bankruptcy Code, 2016 for Noble Explochem Ltd. (NEL) was approved by the National Company Law Tribunal (NCLT) vide its order dated January 22, 2020. Pursuant thereto, the Company has discharged its total obligation and has acquired control over NEL's vast land bank and infrastructure facility near Nagpur. As per the Resolution Plan, on approval by the NCLT, NEL merged with the Company with effect from the Completion Date without obtaining any separate order from NCLT. As per the aforesaid plan NEL's entire capital gets cancelled. The Company has recognised immovable properties, plant and machineries and other assets acquired at its respective fair value in terms of Ind AS 16 on Property, Plant and Equipment based on valuation reports of authorized valuers appointed by the Resolution Professionals. The Company proposes to use these assets to set up manufacturing unit(s) for manufacturing of Drug Intermediates and Active Pharmaceutical Ingredients.
- 3 Being manufacturers of pharmaceuticals, the operations of the Company were exempted from lockdown declared by both the Central and State Governments in the wake of Covid - 19 pandemic. The Company continued with the manufacturing operations at all its manufacturing sites albeit with challenges such as shortage of manpower, availability of materials and disruptions in the logistics and supply chain. The Company has considered the possible effects that may result due to the lockdown announced consequent to outbreak of Covid -19 on the carrying amounts of property, plant and equipment, investments, inventories, receivables and other current assets. Based on internal and external sources of information and economic forecasts, the Company expects the carrying amount of these assets will be recovered and will continue to have sufficient liquidity to fund its business operations as well as expansion plans. However, a definitive assessment of the impact, at this stage, is not possible in view of the highly uncertain economic environment and the situation is still evolving.
- 4 \*The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review.
- 5 The Company has only one reportable primary business segment viz. 'Pharmaceuticals'.
- 6 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,  
Date : June 16, 2020

SIGNED FOR IDENTIFICATION  
BY  
  
G. M. KAPADIA & CO.  
MUMBAI.

By Order of the Board  
For Ipca Laboratories Limited


  
Premchand Godha  
Chairman & Managing Director  
(DIN 00012691)





**Audited Statement of Standalone Cash Flow for the Year ended March 31, 2020**

	2019-20 (₹ Crores)	2018-19 (₹ Crores)
<b>A. Cash Flow from Operating Activities</b>		
1) Net profit before taxation and extraordinary item	784.97	557.39
Adjustments for :		
Depreciation, amortisation and impairment expense	178.69	171.88
(Profit) / Loss on sale of Property, plant & equipment	(7.86)	0.72
Net gain on financial asset through FVTPL	(0.68)	(0.16)
Adjustment on account of Revenue from contract with customers	-	2.04
Property, plant & equipment scrapped/ transferred	1.42	0.86
Miscellaneous Income	-	(1.00)
Sundry balances written off/(back)	(2.00)	(2.34)
Provision for doubtful debts / advances	4.59	0.12
Provision for diminution in value of Investments	1.15	-
Bad debts written off	(0.13)	2.02
Unwinding of Lease Rent	(6.08)	4.38
Employee Stock Option forfeited	-	0.01
Unrealised foreign exchange (gain) / loss	21.76	5.08
Interest income	(31.96)	(27.31)
Interest expense	15.79	18.49
	174.69	174.79
2) Operating profit before working capital changes	959.66	732.18
Decrease / (increase) in inventories	(211.41)	(182.38)
Decrease / (increase) in Trade Receivables	(211.20)	(35.52)
Decrease / (increase) in Other Financial assets	3.17	(6.18)
Decrease / (increase) in Other assets	4.74	2.15
Increase / (Decrease) in Trade Payables	71.31	50.35
Increase / (Decrease) in Other Financial liabilities	(19.64)	1.54
Increase / (Decrease) in Other liabilities	81.94	39.67
Increase / (Decrease) in Provisions	22.19	1.50
	(258.90)	(128.87)
3) Cash generated from operation	700.76	603.31
Income tax paid (net)	(146.41)	(107.66)
Net cash from operating activities	554.35	495.65
<b>B. Cash Flow from Investing Activities</b>		
Purchase of Property, plant & equipment including capital Work in progress and intangible assets	(273.07)	(67.41)
Investment in subsidiaries	(26.74)	(83.40)
Consideration towards Business combination	(108.71)	-
Redemption of investment in subsidiaries	5.12	12.56
Investment in Associates	(49.43)	(14.41)
Investment in Joint Venture	-	(0.33)
Loan given to Associate	14.85	-
Loan given to Joint Venture	1.20	(1.36)
Proceeds from Sale of Property, Plant and Equipment	12.70	1.78
Capital Investment subsidy received	-	14.86
Movement in other bank balances	(116.41)	0.17
Interest received	42.36	14.56
Net cash from / (used) in investing activities	(498.13)	(122.98)
<b>C. Cash Flow from Financing Activities</b>		
Issue of Share Capital	-	4.57
Issue of Share warrant	11.94	-
Increase / (decrease) in short term borrowings	106.69	(40.43)
Repayment of long-term borrowings	(115.22)	(154.91)
Interest paid	(14.32)	(16.66)
Dividend & dividend tax paid	(121.68)	(15.40)
Net cash from (used in) financing activities	(132.59)	(222.83)
Net Increase / (decrease) in cash and cash equivalents (A + B + C)	(76.37)	149.84
Cash and cash equivalents at beginning of year	348.44	198.60
Cash and cash equivalents at end of year	272.07	348.44
Components of cash & cash equivalents :		
Cash and cheques on hand	0.43	0.76
Balance with banks	34.71	257.93
Mutual Funds	238.25	90.38
Less : Fair value (gain) / loss on Mutual funds	(1.32)	(0.63)
	236.93	89.75
	272.07	348.44

Place : Mumbai,  
 Date : June 16, 2020

SIGNED FOR IDENTIFICATION  
 BY   
**G. M. KAPADIA & CO.**  
**MUMBAI.**

By Order of the Board  
 For Ipca Laboratories Limited  
  
**Premchand Godha**  
 Chairman & Managing Director  
 (DIN 00012691)



# G. M. KAPADIA & CO.

(REGISTERED)

CHARTERED ACCOUNTANTS

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE : (91-22) 6611 6611 FAX : (91-22) 6611 6600

## **Independent Auditor's Report on Annual Standalone Financial Results of Ipca Laboratories Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors  
**Ipca Laboratories Limited**  
Mumbai

### **Opinion**

We have audited the accompanying statement of standalone financial results of **Ipca Laboratories Limited** ("the Company") for the year ended March 31, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) is presented in accordance with requirements of Regulation 33 of the Listing Regulations; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company the year ended March 31, 2020.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under SAs are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics issued by ICAI. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



### **Management's Responsibilities for the Statement**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in Ind AS prescribed under section 133 of the Act read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

### **Auditor's Responsibilities for the Audit of the Statement**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain



audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.





**Other Matters**

The Statement includes the results for the quarter ended March 31, 2020 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.



Place: Mumbai  
Dated this 16<sup>th</sup> day of June, 2020

**For G. M. Kapadia & Co.**  
Chartered Accountants  
Firm Registration No. 104767W

**Atul Shah**  
Partner

Membership No. 039569

UDIN: 20039569A\*\*\*E+18144

**Ipca Laboratories Limited**

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067


CIN : L24239MH1949PLC007837

Tel: +91 22 6647 4444, E-mail : investors@ipca.com Website : www.ipca.com

**AUDITED STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020**

(₹ Crores)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2020 Audited*	December 31, 2019 Unaudited	March 31, 2019 Unaudited	March 31, 2020 (Audited)	March 31, 2019 (Audited)
I	Revenue from operations	1073.76	1212.86	879.61	4648.71	3773.18
II	Other Income	13.73	18.13	15.26	67.00	57.68
III	<b>Total Income (I+II)</b>	<b>1087.49</b>	<b>1230.99</b>	<b>894.87</b>	<b>4715.71</b>	<b>3830.86</b>
IV	Expenses					
	a) Cost of materials consumed	377.68	359.92	268.45	1460.37	1106.08
	b) Purchase of stock-in-trade	85.51	96.68	92.22	359.88	249.07
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(98.60)	(32.79)	(53.98)	(176.12)	(115.42)
	d) Employee benefits expense	242.18	231.30	187.10	921.23	787.40
	e) Finance costs	3.67	4.01	6.44	16.50	18.87
	f) Depreciation and amortisation expense	63.94	50.83	44.76	210.50	182.42
	g) Other expenses	298.53	284.09	221.24	1176.65	1054.17
	<b>Total Expenses (IV)</b>	<b>972.91</b>	<b>994.04</b>	<b>766.23</b>	<b>3969.01</b>	<b>3282.59</b>
V	<b>Profit from ordinary activity before share of profit of associate &amp; joint venture, exceptional item &amp; tax (III - IV)</b>	<b>114.58</b>	<b>236.95</b>	<b>128.64</b>	<b>746.70</b>	<b>548.27</b>
VI	Share of Profit / (loss) of associates & joint venture accounted by using the equity method	(2.33)	(2.52)	(0.97)	(7.81)	(1.81)
VII	<b>Profit before exceptional items and tax (V+VI)</b>	<b>112.25</b>	<b>234.43</b>	<b>127.67</b>	<b>738.89</b>	<b>546.46</b>
VIII	Exceptional items	-	-	-	-	-
IX	<b>Profit before tax (VII - VIII)</b>	<b>112.25</b>	<b>234.43</b>	<b>127.67</b>	<b>738.89</b>	<b>546.46</b>
X	Tax Expense					
	Current tax	28.91	40.95	30.98	140.59	121.81
	Short / (Excess) provision of earlier years	0.33	-	(0.42)	0.52	(5.44)
	Deferred tax liability / (asset) including MAT credit	(0.04)	(4.06)	1.09	(5.78)	(12.13)
XI	<b>Profit for the period from continuing operations (IX-X)</b>	<b>83.05</b>	<b>197.54</b>	<b>96.02</b>	<b>603.56</b>	<b>442.22</b>
XII	<b>Other Comprehensive Income</b>					
	A. (i) Items that will not be reclassified to profit or loss					
	-Actuarial gain/(loss)	(2.83)	(0.61)	(4.66)	(7.40)	(1.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.50	0.11	1.00	1.30	0.30
	B. (i) Items that will be reclassified to profit or loss					
	-Exchange difference in translating the financial statement of foreign operation	3.93	4.06	(0.93)	11.10	1.07
	-Gain/(loss) on cash flow hedge	(0.76)	0.12	(0.36)	(1.47)	(3.41)
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.24	(0.04)	-	0.36	-
	C. Share of OCI from investment in associates	0.01	(0.13)	(0.16)	(0.36)	(0.40)
	<b>Other Comprehensive Income / (Loss) for the period, net of tax</b>	<b>1.09</b>	<b>3.51</b>	<b>(5.11)</b>	<b>3.53</b>	<b>(3.83)</b>
XIII	<b>Total Comprehensive Income for the period (XI + XII)</b>	<b>84.14</b>	<b>201.05</b>	<b>90.91</b>	<b>607.09</b>	<b>438.39</b>
	<b>Profit for the year attributable to :</b>					
	Owners of the parent	86.01	197.61	98.55	606.32	444.83
	Non-controlling interest - profit / (loss)	(2.96)	(0.07)	(2.53)	(2.76)	(2.61)
		<b>83.05</b>	<b>197.54</b>	<b>96.02</b>	<b>603.56</b>	<b>442.22</b>
	<b>Other Comprehensive Income for the year attributable to :</b>					
	Owners of the parent	0.64	3.43	(3.72)	2.68	(3.08)
	Non-controlling interest - profit / (loss)	0.45	0.08	(1.39)	0.85	(0.75)
		<b>1.09</b>	<b>3.51</b>	<b>(5.11)</b>	<b>3.53</b>	<b>(3.83)</b>
	<b>Total Comprehensive Income for the year attributable to :</b>					
	Owners of the parent	86.65	201.04	94.83	609.00	441.75
	Non-controlling interest - profit / (loss)	(2.51)	0.01	(3.92)	(1.91)	(3.36)
		<b>84.14</b>	<b>201.05</b>	<b>90.91</b>	<b>607.09</b>	<b>438.39</b>
XIV	Paid-up equity share capital (Face value of ₹ 2/- each)	25.27	25.27	25.27	25.27	25.27
XV	Other Equity	-	-	-	3590.27	3097.12
XVI	Share Warrant	-	-	-	11.94	-
XVII	<b>Net Worth</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3627.48</b>	<b>3122.39</b>
XVIII	<b>Earning per equity share ( of ₹ 2/- each) (Not annualised):</b>					
	Basic ( ₹ )	6.57	15.63	7.60	47.77	35.01
	Diluted ( ₹ )	6.57	15.63	7.60	47.73	35.01



## AUDITED STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT MARCH 31, 2020

		(₹ Crores)	
Sr. No.	Particulars	March 31, 2020 (Audited)	March 31, 2019 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non Current Assets :</b>		
(a)	Property, plant and equipment	1896.32	1746.47
(b)	Capital work-in-progress	70.80	36.09
(c)	Goodwill on consolidation	38.83	23.59
(d)	Goodwill on acquisition	23.61	23.61
(e)	Other Intangible assets	121.90	146.71
(f)	Intangible assets under development	14.42	30.24
(g)	Right of use asset	26.13	-
(h)	Investment accounted for using the equity method	33.66	30.05
(i)	Financial Assets		
	(i) Investments	37.65	-
	(ii) Loans	99.41	117.01
	(iii) Others	11.22	3.24
(j)	Deferred tax assets (net)	2.01	1.84
(k)	Other non-current assets	28.16	14.07
	<b>Total Non current assets</b>	<b>2404.12</b>	<b>2,172.92</b>
<b>2</b>	<b>Current Assets :</b>		
(a)	Inventories	1323.12	1072.50
(b)	Financial Assets		
	(i) Investments	238.25	90.38
	(ii) Trade receivables	895.20	681.51
	(iii) Cash and cash equivalents	58.46	281.18
	(iv) Bank balance other than (iii) above	122.46	1.12
	(v) Loans	2.95	2.57
	(vi) Others	81.04	105.13
(c)	Current tax assets (net)	-	-
(d)	Other current assets	134.23	143.36
	<b>Total Current assets</b>	<b>2855.71</b>	<b>2377.75</b>
	<b>Total Assets</b>	<b>5259.83</b>	<b>4550.67</b>
	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity :</b>		
(a)	Equity Share Capital	25.27	25.27
(b)	Share Warrants	11.94	-
(c)	Other Equity	3590.27	3097.12
	Equity attributable to shareholders of the Holding Company	3627.48	3122.39
	Non controlling interest	13.63	15.54
	<b>Total Equity</b>	<b>3641.11</b>	<b>3137.93</b>
<b>2</b>	<b>Liabilities :</b>		
<b>I</b>	<b>Non Current Liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	102.97	140.85
	(ii) Lease Liability	13.02	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	32.23	25.28
(c)	Deferred tax liabilities (net)	141.82	147.55
(d)	Other non-current liabilities	2.26	1.56
	<b>Total Non current liabilities</b>	<b>292.30</b>	<b>315.24</b>
<b>II</b>	<b>Current Liabilities :</b>		
(a)	Financial Liabilities		
	(i) Borrowings	310.95	209.69
	(ii) Lease Liability	5.87	-
	(iii) Trade payables		
	Dues of Micro and small enterprises	8.28	4.34
	Dues of others	601.57	519.98
	(iv) Other financial liabilities	139.37	197.59
(b)	Current tax liabilities (net)	7.35	18.35
(c)	Provisions	93.70	70.40
(d)	Other current liabilities	159.33	77.15
	<b>Total Current liabilities</b>	<b>1326.42</b>	<b>1097.50</b>
	<b>Total Equity and Liabilities</b>	<b>5259.83</b>	<b>4550.67</b>



**Notes:**

- 1 The above audited consolidated financial statements relates to Ipca Laboratories Ltd. and its Subsidiary Companies, Associates and Joint Venture. The consolidated financial statements have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015
- 2 The above audited consolidated financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on June 16, 2020.
- 3 The Holding Company's Resolution Plan under the Insolvency and Bankruptcy Code, 2016 for Noble Explochem Ltd. (NEL) was approved by the National Company Law Tribunal (NCLT) vide its order dated January 22, 2020. Pursuant thereto, the Holding Company has discharged its total obligation and has acquired control over NEL's vast land bank and infrastructure facility near Nagpur. As per the Resolution Plan, on approval by the NCLT, NEL merged with the Holding Company with effect from the Completion Date without obtaining any separate order from NCLT. As per the aforesaid plan NEL's entire capital gets cancelled. The Holding Company has recognised immovable properties, plant and machineries and other assets acquired at its respective fair value in terms of Ind AS 16 on Property, Plant and Equipment based on valuation reports of authorized valuers appointed by the Resolution Professionals. The Holding Company proposes to use these assets to set up manufacturing unit(s) for manufacturing of Drug Intermediates and Active Pharmaceutical Ingredients.
- 4 Being manufacturers of pharmaceuticals, the operations of the Company in India were exempted from lockdown declared by both the Central and State Governments in the wake of Covid - 19 pandemic. The Group continued with the manufacturing operations at all its manufacturing sites albeit with challenges such as shortage of manpower, availability of materials and disruptions in the logistics and supply chain. The Group has considered the possible effects that may result due to the lockdown announced consequent to outbreak of Covid -19 on the carrying amounts of property, plant and equipment, investments, inventories, receivables and other current assets. Based on internal and external sources of information and economic forecasts, the Group expects the carrying amount of these assets will be recovered and will continue to have sufficient liquidity to fund its business operations as well as expansion plans. However, a definitive assessment of the impact, at this stage, is not possible in view of the highly uncertain economic environment and the situation is still evolving.
- 5 In accordance with Ind AS-108 "Operating Segments", the Group has only one reportable primary business segment i.e. Pharmaceuticals. However, the Group has secondary geographical segment which is disclosed in Consolidated Financial Statements as per Ind AS-108.


Information about secondary geographical segments as per Consolidated Financial Statements:

(₹ Crores)		
Particulars	2019-20	2018-19
Segment Revenue		
- India	2470.48	1860.20
- Outside India	2178.23	1912.98
Total	4648.71	3773.18


The segment asset and segment capital expenditure attributable to the segment "outside India" is less than 10% of the respective total asset and total capital expenditure and therefore not disclosed separately.


- 6 \*The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review.
- 7 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,  
Date : June 16, 2020

SIGNED FOR IDENTIFICATION  
BY  
  
G. M. KAPADIA & CO.  
MUMBAI.

By Order of the Board  
For Ipca Laboratories Limited

  
Premchand Godha  
Chairman & Managing Director  
(DIN 00012691)



**Audited Statement of Consolidated Cash Flow for the Year ended March 31, 2020**

	2019-20 (₹ Crores)	2018-19 (₹ Crores)
<b>A. Cash Flow from Operating Activities</b>		
1) Net profit before taxation and extraordinary item	738.89	546.46
Adjustments for :		
Depreciation and Amortisation	210.50	182.42
Impairment of Intangibles	27.64	-
(Profit) / Loss on sale of Property, plant & equipment	(7.81)	0.63
Share of profit / (loss) of Associates & Joint venture accounted by using the equity method	7.81	1.81
Net gain on financial asset through FVTPL	(0.68)	(0.16)
Adjustment on account of Revenue from contract with customers	-	2.04
Interest income on financial assets at amortised cost	(5.36)	(5.06)
Property, plant & equipment scrapped/ transferred	1.42	0.92
Miscellaneous Income	-	(1.00)
Sundry balances written off/(back)	(2.60)	(2.34)
Provision for doubtful debts / advances	4.56	0.12
Bad debts written off	0.44	2.02
Unwinding of Lease Rent	(6.08)	4.38
Employee Stock Option forfeited	-	0.01
Unrealised foreign exchange (gain) / loss	21.89	5.08
Interest income	(26.94)	(22.38)
Interest expense	16.50	18.87
2) Operating profit before working capital changes	980.18	733.82
Decrease / (Increase) in inventories	(239.86)	(191.91)
Decrease / (increase) in Trade Receivables	(187.41)	(75.49)
Decrease / (increase) in Other Financial assets	4.13	(4.41)
Decrease / (increase) in Other assets	7.50	2.47
Increase / (Decrease) in Trade Payables	68.28	101.88
Increase / (Decrease) in Other Financial liabilities	(20.81)	(0.29)
Increase / (Decrease) in Other liabilities	82.71	44.28
Increase / (Decrease) in Provisions	21.77	1.50
3) Cash generated from operation	716.49	611.85
Income tax paid (net)	(152.22)	(110.82)
Net cash from operating activities	564.27	501.03
<b>B. Cash Flow from Investing Activities</b>		
Purchase of Property, plant & equipment, Intangibles including Capital Work in progress	(306.28)	(180.54)
Consideration towards Business combination	(108.72)	-
Investment including Equity Shares, Share Warrants and Preference Shares in Associates	(49.43)	(14.41)
Investment in Joint Venture	-	(0.33)
Loan given to Associate	14.85	-
Loan given to Joint Venture	1.20	(1.36)
Proceeds from Sale of Property, Plant and Equipment	12.65	1.87
Capital Investment subsidy received	-	14.86
Movement in other bank balances	(116.62)	0.16
Interest received	42.70	14.69
Net cash from / (used) in Investing activities	(509.65)	(165.06)
<b>C. Cash Flow from Financing Activities</b>		
Issue of Share Capital	-	4.57
Issue of Share Warrant	11.94	-
Increase / (decrease) in short term borrowings	91.30	(26.60)
Proceeds from long-term borrowings	24.58	6.91
Repayment of long-term borrowings	(122.19)	(154.91)
Increase in Minority Interest	-	18.90
Interest paid	(14.43)	(16.66)
Dividend & dividend tax paid	(121.66)	(15.41)
Net cash from (used in) financing activities	(130.46)	(183.20)
Net Increase / (decrease) In cash and cash equivalents ( A + B + C )	(75.84)	152.77
Cash and cash equivalents at beginning of year	370.92	218.15
Movement due to Business Acquisition	0.31	-
Cash and cash equivalents at end of year	295.39	370.92
Components of cash & cash equivalents :		
Cash and cheques on hand	0.48	1.14
Balance with banks	57.98	280.04
Mutual Funds	238.25	90.38
Less : Fair value (gain) / loss on Mutual funds	(1.32)	(0.64)
	295.39	370.92

Place : Mumbai,  
 Date : June 16, 2020

SIGNED FOR IDENTIFICATION  
 BY

G. M. KAPADIA & CO.  
 MUMBAI.

By Order of the Board  
 For Ipca Laboratories Limited

Premchand Godha  
 Chairman & Managing Director  
 (DIN 00012691)



# G. M. KAPADIA & CO.

(REGISTERED)

CHARTERED ACCOUNTANTS

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE : (91-22) 6611 6611 FAX : (91-22) 6611 6600

## Independent Auditor's Report on Audit of Annual Consolidated Financial Results of Ipca Laboratories Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors  
**Ipca Laboratories Limited**  
Mumbai


### Opinion

We have audited the accompanying statement of consolidated financial results of **Ipca Laboratories Limited** (hereinafter referred to as "the Holding Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the Group) and its joint venture and associates for the year ended March 31, 2020 ("Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the quarter ended March 31, 2019, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review / audit.

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of other auditors on standalone financial statements and other financial information of subsidiaries, joint venture and associates, the aforesaid statement:

(i) includes the standalone financial results of the following entities:

Sr. No.	Name of the Entities
	<b>Subsidiaries</b>
1	Ipca Pharma Nigeria Limited, Nigeria
2	Ipca Pharmaceuticals Limited, SA. de CV, Mexico
3	Ipca Laboratories (U.K.) Limited, UK
4	Ipca Pharmaceuticals Inc. USA
5	Ipca Pharma (Australia) Pty Limited, Australia
6	Tonira Exports Limited, India
7	Ramdev Chemicals Private Limited, India
	<b>Step Down Subsidiaries</b>
8	Onyx Scientific Limited, UK
9	Ipca Pharma (NZ) Pty Limited, New Zealand
10	Pisgah Labs Inc., USA



Sr. No.	Name of the Entities
11	Bayshore Pharmaceuticals LLC, USA
	<b>Joint Venture</b>
12	Avik Pharmaceuticals Limited, India
	<b>Associates</b>
13	Trophic Wellness Private Limited, India
14	Krebs Biochemicals Industries Limited, India

- (ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (“Ind AS”) and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2020.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013 (“Act”). Our responsibilities under SAs are further described in the *Auditor’s Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, its joint venture and its associates in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics issued by ICAI. We believe that the audit evidence obtained by us and other auditors in terms of their report referred to in “Other Matters” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

### **Management’s Responsibilities for the Statement**

This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared on the basis of consolidated financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group its joint venture and its associates in accordance with the recognition and measurement principles laid down in Ind AS prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.



The respective Board of Directors of the companies included in the Group and of its joint venture and associates are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and of its joint venture and associates and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its joint venture and associates are responsible for assessing the ability of the Group and of its joint venture and associates to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the entity or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its joint venture and associates are responsible for overseeing the financial reporting process of the Group and of its joint venture and associates.

#### **Auditor's Responsibilities for the Audit of the Statement**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.





- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report the complete set of consolidated financial statements on whether the Group, its joint venture and its associates has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, its joint venture and its associates to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group, its joint venture and its associates to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results and other financial information of the Group, its joint venture and its associates to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding,



among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### **Other Matters**

- (i) The Statement include (a) the audited standalone financial results of eight subsidiaries (including six foreign subsidiaries), whose standalone financial statements reflect total assets of Rs. 632.91 crores as at March 31, 2020, total revenue of Rs. 305.27 crores, total net loss of Rs. 37.36 crores, total comprehensive loss of Rs. 9.84 crores and net cash inflows of Rs. 0.58 crores for the year ended March 31, 2020, as considered in the Statement; and (b) the Group's share of the net loss of Rs. 7.42 crores and total comprehensive loss of Rs. 11.65 crores for the year ended March 31, 2020 as considered in the preparation of the Statement, in respect two associates and one joint venture. These financial results and other financial information have been audited by their respective independent auditors whose reports have been furnished to us by the Management of the Company and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint venture and associates is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above. The Statement also includes the unaudited financial results of three foreign subsidiaries, whose financial statements reflect total assets of Rs. 0.54 crores as at March 31, 2020, total revenue of Rs. 0.13 crores, total net loss of Rs. 0.02 crores, total comprehensive loss of Rs. 0.05 crores and net cash outflows of Rs. 0.06 crores for the year ended March 31, 2020, as considered in the preparation of the Statement. The financial statements and financial information of these subsidiaries are unaudited and have been certified by the Management. Our opinion on the Statement in so far as it relates to these three subsidiaries is based solely on such management certified unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management of the Company, these financial statements are not material to the Group.
- (ii) The Management of the Company has also furnished us details of adjustment that are required in case of financial statements of foreign subsidiaries so as to make these financial statements fit for consolidation. Our opinion on the Statement is not modified




in respect of above matters with respect to our reliance on the work done and the report of the other auditors and the standalone financial statements and other financial information certified by the Management of the Holding Company.

- (iii) The Statement includes the results for the quarter ended March 31, 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**For G. M. KAPADIA & Co.**

Chartered Accountants

Firm Registration No.104767W



A handwritten signature in black ink, appearing to read "Atul Shah".

**Atul Shah**

Partner

Membership No.039569

UDIN: 20039569AAAAEI2962

Place: Mumbai

Dated this 16<sup>th</sup> day of June, 2020

June 16, 2020

BSE Limited  
Phiroze Jeejeebhoy Towers  
27<sup>th</sup> Floor, Dalal Street  
Mumbai 400 023


The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Flr, Plot # C/1  
G Block, Bandra-Kurla Complex,  
Bandra (E), Mumbai 400 051.

Dear Sirs,

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time and SEBI Circular No. Cir/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the M/s. G. M. Kapadia & Co., Statutory Auditors of the Company have issued Audit Reports with unmodified opinion on the Audited Financial Statements of the Company (both for Standalone & Consolidated) for the financial year ended 31<sup>st</sup> March, 2020.


Yours faithfully

For Ipca Laboratories Limited



A. K. Jain  
Joint Managing Director /CFO

For Ipca Laboratories Limited



Harish Kamath  
Corporate Counsel & Company Secretary

**Ipca Laboratories Ltd.**  
**www.ipca.com**

## PRESS RELEASE

### Ipca Laboratories Q4 FY20 Financial Results


**Mumbai, June 16, 2020** : Ipca Laboratories Limited today announced its audited financial results for the fourth quarter and financial year ended 31<sup>st</sup> March, 2020.

#### Key Financials of Q4 FY20

- Standalone Net total Income up 20% at Rs. 1018.09 crores.
- Consolidated Net total Income up 22% at Rs. 1087.49 crores.
- Indian formulations income up 21% at Rs. 430.96 crores.
- Exports Income up 18% at Rs. 492.66 crores.
- Standalone EBITDA margin (before forex (gain)/loss) @ 22.29% in Q4 FY20 as against @ 21.20% in Q4 FY19.
- Consolidated EBITDA margin @ 21.47% in Q4 FY20 as against @ 20.09% in Q4 FY19.
- Standalone Net Profit at Rs. 127.76 crores up 17%.
- Consolidated Net Profit at Rs. 83.05 crores decreased by 14% after impairment of Intangible Assets of Rs. 27.64 crores of a US subsidiary.

Standalone Q4 FY20 at a glance			(Rs. Crores)
Particulars	Q4 FY20	Q4 FY19	Growth
Net Total Income	1018.09	848.39	20%
Export Income	492.66	419.16	18%
EBITDA before Forex (gain) / loss	226.90	179.90	26%
Forex (gain) / loss	20.88	(9.35)	-
Finance Cost	3.47	6.25	-44%
Depreciation and Amortisation	45.38	41.61	9%
Tax Expense	29.41	31.92	-8%
Net Profit after tax	127.76	109.47	17%
Earnings per share of Rs. 2/- each (Rs.)	10.11	8.67	17%

Consolidated Q4 FY20 at a glance			(Rs. Crores)
Particulars	Q4 FY20	Q4 FY19	Growth
Consolidated Net Total Income	1087.49	894.87	22%
Consolidated EBITDA before Forex (gain) / loss and impairment	233.45	179.80	30%
Share of (profit) / loss of associates & joint venture	2.33	0.97	140%
Forex (gain) / loss	23.62	(0.04)	-
Finance Cost	3.67	6.44	-43%
Depreciation and Amortisation	63.94	44.76	43%
Impairment of Intangible Assets	27.64	-	-
Tax Expense	29.20	31.65	-8%
Consolidated Net Profit after tax	83.05	96.02	-14%
Consolidated Earnings per share of Rs. 2/- each (Rs.)	6.57	7.60	-14%



**Ipca Laboratories Ltd.**  
[www.ipca.com](http://www.ipca.com)

135, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005  
 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444  
 E: [ipca@ipca.com](mailto:ipca@ipca.com) CIN: L24239MH1949PLC007837

Q4 FY20 Revenue break-up		(Rs. Crores)	
Particulars	Q4 FY20	Q4 FY19	Growth
<b>Formulations</b>			
Domestic	430.96	355.70	21%
<b>Exports</b>			
Branded	76.72	94.59	-19%
Institutional	39.71	40.82	-3%
Generics	166.04	118.19	40%
<b>Total Formulations</b>	<b>713.43</b>	<b>609.30</b>	<b>17%</b>
<b>APIs</b>			
Domestic	64.88	46.04	41%
Exports	210.19	165.56	27%
<b>Total APIs</b>	<b>275.07</b>	<b>211.60</b>	<b>30%</b>
Other Operating Income	16.29	12.91	26%
Standalone Revenue from Operations	1004.79	833.81	21%
Revenue from Operations - Subsidiaries	68.97	45.80	51%
Consolidated Revenue from Operations	1073.76	879.61	22%
Other Income	13.73	15.26	-10%
<b>Consolidated Net Total Income</b>	<b>1087.49</b>	<b>894.87</b>	<b>22%</b>

#### Key Financials of FY20

- Standalone Net Total Income up 20% at Rs. 4432.12 crores.
- Consolidated Net Total Income up 23% at Rs. 4715.71 crores.
- Indian formulations income up 16% at Rs. 1912.61 crores.
- Exports Income up 24% at Rs. 2143.75 crores.
- Standalone EBITDA margin (before forex (gain) / loss) @ 22.41% in FY20 as against @ 20.75% in FY19
- Consolidated EBITDA margin @ 21.55% in FY20 as against @ 20.05% in FY19
- Standalone Net Profit at Rs. 652.46 crores up 43%.
- Consolidated Net Profit at Rs. 603.56 crores up 36%

Standalone FY20 at a glance		(Rs. Crores)	
Particulars	FY20	FY19	Growth
Net Total Income	4432.12	3687.74	20%
Export Income	2143.75	1730.84	24%
EBITDA before Forex (gain) / loss	993.41	765.26	30%
Forex (gain) / loss	13.96	17.50	-20%
Finance Cost	15.79	18.49	-15%
Depreciation and Amortisation	178.69	171.88	4%
Tax Expense	132.51	102.48	29%
Net Profit after tax	652.46	454.91	43%
Earnings per share of Rs. 2/- each (Rs.)	51.64	36.01	43%

**Ipca Laboratories Ltd.**  
[www.ipca.com](http://www.ipca.com)

Consolidated FY20 at a glance		(Rs. Crores)	
Particulars	FY20	FY19	Growth
Consolidated Net Total Income	4715.71	3830.86	23%
Consolidated EBITDA before Forex (gain) / loss and impairment	1016.40	768.20	32%
Share of (profit) / loss of associates & joint venture	7.81	1.81	-
Forex (gain) / loss	15.06	18.64	-19%
Finance Cost	16.50	18.87	-13%
Depreciation and Amortisation	210.50	182.42	15%
Impairment of Intangible Assets	27.64	-	-
Tax Expense	135.33	104.24	30%
Consolidated Net Profit after tax	603.56	442.22	36%
Consolidated Earnings per share of Rs. 2/- each (Rs.)	47.77	35.01	36%

FY20 Revenue break-up		(Rs. Crores)	
Particulars	FY20	FY19	Growth
<b>Formulations</b>			
Domestic	1912.61	1646.83	16%
<b>Exports</b>			
Branded	381.53	360.94	6%
Institutional	176.31	164.95	7%
Generics	663.71	522.37	27%
<b>Total Formulations</b>	<b>3134.16</b>	<b>2695.09</b>	<b>16%</b>
<b>APIs</b>			
Domestic	250.93	201.98	24%
Exports	922.20	682.58	35%
<b>Total APIs</b>	<b>1173.13</b>	<b>884.56</b>	<b>33%</b>
Other Operating Income	60.14	53.50	12%
Standalone Revenue from Operations	4367.43	3633.15	20%
Revenue from Operations - Subsidiaries	281.28	140.03	101%
Consolidated Revenue from Operations	4648.71	3773.18	23%
Other Income	67.00	57.68	16%
<b>Consolidated Net Total Income</b>	<b>4715.71</b>	<b>3830.86</b>	<b>23%</b>

#### About Ipca Laboratories:

Ipca is a pharmaceutical company with a strong thrust on exports which now account for 48% of Company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients.

  
 Premchand Godha  
 Chairman & Managing Director



Encl: Audited Standalone & Consolidated Financial Results

#### Contact Information:

Harish P. Kamath, Corporate Counsel & Company Secretary at [harish.kamath@ipca.com](mailto:harish.kamath@ipca.com) or on +91-22- 6210 6050

**Ipca Laboratories Ltd.**  
[www.ipca.com](http://www.ipca.com)

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005  
 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444  
 E: [ipca@ipca.com](mailto:ipca@ipca.com) CIN: L24239MH1949PLC007837